anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Blow flies (Diptera: Calliphoridae) are frequently used in forensic investigations due to their rapid colonization of cadavers. As with other insects, environmental temperature strongly influences their developmental rates. While published research has typically explored not only the impact of the environmental temperature, but also of other factors like tissue type and drug presence on developmental rates, the influence of photoperiod on the developmental rates of forensically relevant blow fly species has remained largely underexplored. Understanding the relationship between photoperiod and developmental times is crucial, as neglecting this aspect could compromise the accuracy of minimum post-mortem interval (minPMI) estimations. The present study investigates the impact of three photoperiod conditions (0:24, 8:16, and 12:12 light:darkness) on the developmental rates of Calliphora vicina, focusing on the duration of the different immature stages and on the total developmental time. Our results revealed significant variation in the intra-puparial stage and total development time across different photoperiods. Notably, a 12:12 photoperiod led to a significantly prolonged intra-puparial stage and total development time compared to the 0:24 photoperiod, suggesting that Calliphora vicina develops faster in total darkness. These findings highlight the importance of considering photoperiod in both laboratory rearing protocols and forensic casework to improve the accuracy and reliability of minPMI estimations. In this regard, preliminary guidelines and recommendations are provided.
OBJECTIVES: I. Determine the maximum tolerated dose and toxicities of intraperitoneal adenoviral p53 gene therapy in patients with advanced, recurrent, or persistent ovarian carcinoma. II. Evaluate the vector pharmacokinetics and biologic efficacy of gene transfer, gene expression, and cell death in these patients. III. Determine the immunologic response to therapy in these patients.

OUTLINE: This is a dose escalation study of adenoviral p53 gene therapy. Patients undergo removal of ascites, if present, from the peritoneal cavity followed by a bolus infusion of adenovirus p53 once a week for 3 consecutive weeks, followed by a 2 week rest. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients who experience palliative results with at least stable disease may continue treatment weekly without the rest period. Cohorts of 3-6 patients are treated at each level of adenovirus p53. The maximum tolerated dose is defined as the dose level below that at which 2 of 6 patients experience dose limiting toxicity. Patients who receive the MTD without unacceptable toxicity may continue to receive treatment on a weekly basis.

PROJECTED ACCRUAL: Approximately 15-20 patients will be accrued over 16-18 months for this study.
PURPOSE: Risk factors for developing radioiodine refractory thyroid cancer (RAIR-TC) have rarely been analyzed. The purpose of the present study was to find clinical and pathological features associated with the occurrence of RAIR-disease in differentiated thyroid cancers (DTC) and to establish an effective predictive risk score.
METHODS: All cases of RAIR-DTC treated in our center from 1990 to 2020 were retrospectively reviewed. Each case was matched randomly with at least four RAI-avid DTC control patients based on histological and clinical criteria. Conditional logistic regression was used to examine the association between RAIR-disease and variables with univariate and multivariate analyses. A risk score was then developed from the multivariate conditional logistic regression model to predict the risk of refractory disease occurrence. The optimal cut-off value for predicting the occurrence of RAIR-TC was assessed by receiver operating characteristic (ROC) curves and Youden's statistic.
RESULTS: We analyzed 159 RAIR-TC cases for a total of 759 controls and found 7 independent risk factors for predicting RAIR-TC occurrence: age at diagnosis ≥ 55, vascular invasion, synchronous cervical, pulmonary and bone metastases at initial work-up, cervical and pulmonary recurrence during follow-up. The predictive score of RAIR-disease showed a high discrimination power with a cut-off value of 8.9 out of 10 providing 86% sensitivity and 92% specificity with an area under the curve (AUC) of 0.95.
CONCLUSION: Predicting the occurrence of RAIR-disease in DTC patients may allow clinicians to focus on systemic redifferentiating strategies and/or local treatments for metastatic lesions rather than pursuing with ineffective RAI-therapies.
PURPOSE:To obtain an extract containing medicinal active ingredients contained in the bark of Eucommia ulmoides by extracting the seeds of Eucommia ulmoides. CONSTITUTION:The seeds of Eucommia ulmoides, pref. current seeds collected in their maturity are ground and extracted using water, ketone, aromatic hydrocarbon, ether, etc., (pref. a mixture of water and lower alcohol). The resulting liquid extract is concentrated under reduced pressure, thus obtaining the objective extract. The extract contains medicinal active ingredients contained in the bark, in particular, such ones as to have marked vasodepressor activity (e.g pinoresinol-di-O-beta-D-glucoside, aucubin, syringin, liriodendrin, etc., and also contains new iridoid glycoside of the formula (R is H or acyl; n is 1 or 2). With the present method, the objective extract can be obtained without the need for much labor as the case with the collection from grown Eucommia ulmoides and without having adverse effect on the growth or existence of the grown Eucommia ulmoides.
30,405-00 .DELTA.22-DERIVATIVES OF LL-F28249 COMPOUNDS                           ABSTRACT OF THE INVENTION The present invention relates to novel deriva-tives of LL-F28249 compounds.  These LL-F28249 compounds preferably are derived via a controlled microbiological fermentation of Streptomyces cvaneoariseus subsp.  non-cvanoaenus having deposit accession number NRRL 15773. The derivatives of the present invention have the 23-hydroxy group react to form a double bond in the 22,23 position.  The novel derivatives of the present invention possess activity as anthelmintic, ectoparasitic, insecti-cidal, acaricidal and nematicidal agents.  They also are useful in areas of human and animal health and in agri-cultural crops.
The present invention provides a composition for promoting sensitivity to anticancer drug in cancer cell or cancer tissue, containing inhibitor for activity or expression of GLRX3. The composition of the present invention increases sensitivity to anticancer drug in an object, resulting in an increase in treating effects of the anticancer drug. In addition, the increase in the anticancer drug sensitivity reduces a dose of anticancer drug used for a parallel treatment, thereby reducing inherent side effects of the anticancer drug for itself. The present invention further provides a method for detecting GLRX3 as a marker tolerant to the anticancer drug by using a specimen from a patient, and also provides a kit for analyzing anticancer drug tolerance. Thus, GLRX3 can be applied as a marker for predicting the anticancer drug tolerance. The present invention also provides a composition for treating cancer exhibiting tolerance to anticancer drug, containing the GLRX3 inhibitor.
Berberine, a natural plant alkaloid, has not been well investigated for clinical application in the treatment of diabetes. The present study evaluated the efficacy and safety of berberine in the treatment of type 2 diabetic patients with dyslipidemia. 116 patients with type 2 diabetes and dyslipidemia were assigned in a randomized, double-blind, and placebo-controlled 4-clinical center study to receive berberine (1.0g daily) or placebo for 3 months. The primary efficacy outcomes were changes in plasma glucose and serum lipid levels. The glucose disposal rate (GDR) was measured using a hyperinsulinemic euglycemic clamp to assess insulin resistance in a randomly selected subjects of 54 patients. The baseline characteristics were similar in berberine and placebo groups. After 3 months, fasting and post load plasma glucose levels, HbA1C, triglyceride, total cholesterol and LDL-C levels were all significantly reduced in the berberine group compared with the placebo group (p\<0.0001, p\<0.0001, p\<0.0001, p=0.002, p\<0.0001 and p\<0.0001 respectively). The GDR was significantly increased after 3 months of berberine (p=0.037), while no change was found in the placebo group (p=0.86). BMI, systolic blood pressure and serum IL-6 levels were all significantly reduced after treatment in berberine group as compared with the placebo group (p=0.016, p=0.041 and p=0.014, respectively). Our results show berberine to be effective and safe in the treatment of persons with diabetes and dislipidemia. This agent may be useful in the treatment of patients with type 2 diabetes, and could play a role in treatment of metabolic syndrome.
BACKGROUND: The Oncotype DX® Breast Recurrence Score assay can guide recommendations made to patients with oestrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer regarding post-surgery adjuvant therapy. Standard practice is to order the test in the post-operative setting on a specimen from the excised invasive carcinoma. However, it has been shown to be technically possible to perform the test on the diagnostic core biopsy. By testing the diagnostic core biopsy in the pre-operative setting, the wait for excised invasive carcinoma Recurrence Score results could be reduced allowing patients to be more accurately counselled regarding their treatment pathway sooner with any adjuvant treatment recommendations expedited. This would allow for more efficient streaming of follow up appointments. The aim of this study is to compare the impact on the patient treatment pathway of performing the Oncotype DX® test on the diagnostic core biopsy pre-operatively (intervention) as opposed to the excised invasive carcinoma (control).
METHODS AND ANALYSIS: This parallel group randomised controlled trial aims to recruit 330 newly diagnosed patients with grade 2 or grade 3, ER+, HER2-, invasive intermediate risk early-stage breast cancer. Participants will be randomised 2:1 to the preoperative testing of the diagnostic core biopsy compared to the post-operative testing of the excision specimen. The primary endpoint is number of clinical touchpoints between treating team and patient from initial approach until offer and prescription of the first adjuvant treatment. Secondary endpoints include time from diagnosis to offer and prescription of the first adjuvant treatment, patient-reported anxiety scores and health cost impact analysis collected at baseline, following the post-operative clinic and following the offer of adjuvant treatment, and number of alterations in treatment sequence from original planned surgical treatment to neoadjuvant therapy.
TRIAL REGISTRATION: The study was registered on ISRCTN (ISRCTN14337451) on the 16th August 2022.
Forty patients with Non-suicidal Self-injury (NSSI) diagnosed by DSM-5 were recruited from the Second Affiliated Hospital of Anhui Medical University. All participants underwent a structured interview and routine laboratory examination before and after receiving high-definition transcranial Direct Current Stimulation (HD-tDCS) treatment after meeting the inclusion criteria and obtaining informed consent. Each participant will complete the clinical evaluation, magnetic resonance imaging (MRI), and HD-tDCS treatment conducted by trained researchers at the Second Affiliated Hospital of Anhui Medical University. All the participants were randomized (1:1) to receive an "active HD-tDCS" or "sham HD-tDCS" treatment protocol. tDCS: the central electrode was placed over F3 with return electrodes placed at Fp1, Fz, F7 and C3. Fourteen 2-mA sessions (ramp-up and ramp-down periods of 15 and 15 seconds, respectively) were applied for 20 minutes per session, twice daily over 7 consecutive days. Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 15 and 15 seconds.

Before and after the treatments, the patients received a battery measure of neuropsychological tests, and MRI scans in multimodalities. The neuropsychological assessment included the Ottawa Self-injury Inventory (OSI), the Adolescent Non-suicidal Self-injury Assessment Questionnaire (ANSAQ), the Hamilton Depression Rating Scale (HAMD), the Hamilton Anxiety Rating Scale (HAMA), and Patient Health Questionnaire-15 (PHQ-15), etc. Multimodal MRI includes 3D-T1, rs-fMRI, and DTI. The symptoms of the patients were followed up one and two months after the end of treatments.
Pulmonary fibrosis (PF) is an interstitial lung disease tightly associated with the disruption of mitochondrial pool homeostasis, a delicate balance influenced by functional and dysfunctional mitochondria within lung cells. Mitochondrial transfer is an emerging technology to increase functional mitochondria via exogenous mitochondrial delivery; however, the therapeutic effect on mitochondrial transfer is hampered during the PF process by the persistence of dysfunctional mitochondria, which is attributed to impaired mitophagy. Herein, we reported engineering mitochondria mediated by mitophagy-enhanced nanoparticle (Mito-MEN), which promoted synchronal regulation of functional and dysfunctional mitochondria for treating PF. Mitophagy-enhanced nanoparticles (MENs) were fabricated through the encapsulation of Parkin mRNA, and the electrostatic interaction favored MENs to anchor isolated healthy mitochondria for the construction of Mito-MEN. Mito-MEN increased the load of functional exogenous mitochondria by enhancing mitochondrial delivery efficiency and promoted mitophagy of dysfunctional endogenous mitochondria. In a bleomycin (BLM)-induced PF mouse model, Mito-MEN repaired mitochondrial function and efficiently relieved PF-related phenotypes. This study provides a powerful tool for synchronal adjustment of mitochondrial pool homeostasis and offers a translational approach for pan-mitochondrial disease therapies.
Cyclic D,L-α-peptides were shown to have an anti-amyloid aggregation effect. The cyclic peptide (designated cyclic peptide-2) having the sequence [1JwHsK], had a drastic effect on amyloid aggregation. However, the linear equivalent of cyclic peptide-2 did not inhibit amyloid formation. Cyclic peptide 2 was also effective in reducing Aβ-induced toxicity in PC12 cells. According to embodiments of the invention, cyclic peptides may comprise between 6 or 8 amino acids. In an embodiment, half of the amino acid residues are in the D-formation, and the other half are in the L-formation. In an embodiment of the invention, the amino acids alternate between the D and L-formations.
Four total capsules per day (2 in the morning; 2 at night) for 29 days. ESPO-572®, a 75/25% PCSO-24®/Krill oil blend. Each capsule of the ESPO-572® contains green lipped mussel oil, krill oil, olive oil and vitamin E.
The present invention relates to a method for determining the presence of a circulating tumor marker in the human body, comprising detecting the tumor marker in the vagina, wherein the tumor marker originates from a part of the body that is not the vagina. In a preferred embodiment, the tumor marker is detected by means of an aptamer. Even more preferably, the aptamer is present in a vaginal ring device. The vaginal ring device suitably comprises a diagnostic device for performing an intravaginal diagnosis or measurement therefor. The method can for example be used in the continuous monitoring of circulating tumor markers in oncologic patients or in the pretreatment and posttreatment follow-up of oncologic patients. The invention further relates to a vaginal diagnostic ring device for performing the method..
The invention comprises 1-methylamino-2-nitro - 4 - (2 - hydroxyethyl) - methylamino benzene.  The compound is prepared by acetylating the hydrogen atom of the 4-amino group of 1-amino-2-nitro-4-methylamino benzene with acetic anhydride, replacing a hydrogen atom of the 1-amino group by reaction with p-toluene-sulphonyl chloride, methylating the resulting product, e.g. with methyl sulphate, removing the p-toluene sulphonyl and acetyl groups by hydrolysis with H2SO4 and HCl respectively and refluxing the resulting product with an ethylene halohydrin.  The ethylene halohydrin may be ethylene bromohydrin.ALSO:The invention comprises 1-methylamino-2-nitro - 4 - (2 - hydroxyethyl) - methylamino benzene. The compound is prepared by acetylating the hydrogen atom of the 4-amino group of 1-amino-2-nitro-4-methylamino benzene with acetic anhydride, replacing a hydrogen atom of the 1-amino group by reaction with p-toluene sulphonyl chloride, methylating the resulting product, e.g. with methyl sulphate, removing the p-toluene sulphonyl and acetyl groups by hydrolysis with H2SO4 and HCl respectively and refluxing the resulting product with an ethylene halohydrin.  The ethylene halohydrin may be ethylene bromohydrin.ALSO:Compositions containing 1-methylamino-2-nitro-4-(2-hydroxyethyl)-methylamino benzene are used to dye hair.  The composition may also include other nitro, azo or anthraquinone dyes.  The dyes are preferably used at alkaline pH.  Other additives that may be present include organic solvents, detergents, thickening agents and lacquers.  The dyes do not require the presence of an oxidising agent.
A person with a proven bacterial infection (105 colony-forming units/mL for tracheal aspirates and more than 104 colony-forming units/mL for BAL). Additional tubes taken when blood is drawn during treatment, and bronchoalveolar fluid sample.
Assessment of seropersistence of TBE antibodies at yearly intervals from approximately 3 years (38 months) to 10 years (118 months) after the first booster vaccination (in Study 700401), as well as antibody response to a second booster vaccination with either FSME-IMMUN 0.25 mL Junior or FSME-IMMUN 0.5 mL, depending on the subject´s age. Timing of the second booster vaccination will depend on the level of serum TBE antibodies detected at the defined assessment time points. Subjects who are not protected against TBE for an entire further season (NT titer \<= 20 and/or ELISA value \<=126 VIE U/mL) will be invited to receive the second booster vaccination at either the 40, 48, 60, 72, 84, 96, 108, or 120-month time point.
The invention discloses a cell penetrating peptide, a conjugate comprising the same and application thereof. Specifically, cell penetrating peptides having one of SEQ ID NO. 2 to SEQ ID NO. 178, conjugates of peptides comprising fragments of one of SEQ ID NO. 2 to SEQ ID NO. 178, or conjugates comprising peptides having at least 80% homology to the peptide sequences, and compositions comprising the conjugates are disclosed.
The proposed clinical trial will evaluate the efficacy of FST-201 (dexamethasone 0.1% with povidone-iodine 1% ) Otic Suspension vs. the FDA-approved drug Ciprodex (ciprofloxacin 0.3%, dexamethasone 0.1%) Otic Suspension (Alcon Laboratories, Inc.) in the treatment of acute otitis externa. Acute otitis externa is a common inflammatory condition of the external auditory canal often associated with infection, allergy and dermatitis. The active ingredient in our novel dexamethasone suspension is identical in concentration and route of administration to the steroid component of the approved drug Ciprodex, which is currently the most widely-prescribed dexamethasone-containing agent in the treatment of acute otitis externa. We will enroll 60 patients (30 each in two separate treatment groups) in this trial. All patients electing to participate in this study will receive either FST-201 or Ciprodex. FST-201 and Ciprodex will be masked and provided free of charge to all study participants. Patients will be followed for at least 15 days or until their ear inflammation is either resolved or determined to need additional interventions. The study will be conducted with attention to all relevant Good Clinical Practice (GCP), International Conference on Harmonization (ICH), FDA, Health Insurance Portability and Accountability Act (HIPPA) and Declaration of Helsinki guidelines.
FIELD: molecular biology, genetic engineering, medicine. SUBSTANCE: DNA sequence encoding the novel antagonist of interleukin-1 receptor (ic IL + 1raII) is characterized. By insertion of this sequence in vector plasmid pSF5 and transformation of COS-cells with constructed expressing vector the expression of recombinant polypeptide with molecular mass about 25 kDa is achieved. Polypeptide shows inhibitory activity with respect to IL-Ia and IL-1b that is comparable with activity of intercellular form of antagonist of interleukin-1 receptor icIL + 1ra. Invention describes the use of novel antagonist of receptor IL-1 as active component in pharmaceutical composition used in pathologies associated with IL-1 producing. EFFECT: valuable medicinal properties of antagonist. 8 cl, 8 dwg, 1 ex
STRATTERA (atomoxetine) increased the risk of suicidal ideation in short-term studies in children or adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). Anyone considering the use of STRATTERA in a child or adolescent must balance this risk with the clinical need. Co-morbidities occurring with ADHD may be associated with an increase in the risk of suicidal ideation and/or behavior. Patients who are started on therapy should be monitored closely for suicidality (suicidal thinking and behavior), clinical worsening, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. STRATTERA is approved for ADHD in pediatric and adult patients. STRATTERA is not approved for major depressive disorder.

Pooled analyses of short-term (6 to 18 weeks) placebo-controlled trials of STRATTERA in children and adolescents (a total of 12 trials involving over 2200 patients, including 11 trials in ADHD and 1 trial in enuresis) have revealed a greater risk of suicidal ideation early during treatment in those receiving STRATTERA compared to placebo. The average risk of suicidal ideation in patients receiving STRATTERA was 0.4% (5/1357 patients), compared to none in placebo-treated patients (851 patients). No suicides occurred in these trials [see Warnings and Precautions (5.1)].
FIELD: medicine. SUBSTANCE: system has flexible material strip of rigidity enough to assume curved shape on the adjacent teeth set and dental white agent. The material strip is fittable to dental surface and to interdental space between the adjacent teeth with no residual deformation when placing the system on the teeth. Dental white agent is gel covering the material strip so that it touches the dental surface when placed thereon delivering the active ingredient to the dental surface. The agent also enables the strip adhesion to the dental surface to take place for retaining the delivery system on its place during the time period enough for giving the active ingredient time to exert its action upon the surface. Delivery method involves using strip with sticky substance applied in advance or smearable by user himself with its following application to the dental surface. EFFECT: low cost remedy; enabled tooth whitening in hardly accessible places under arbitrary conditions. 10 cl, 10 dwg